SCHEMBL13792182

SCHEMBL13792182

CC(C)(C)N1CCC2(CC1)CC(=O)Nc1ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.47
OPRM1 P35372 2/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
GRIN1 Q05586 1/20 0.46
KCNH2 Q12809 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
CCR5 P51681 2/20 0.40
PDE7A Q13946 1/20 0.37
CRBN Q96SW2 3/20 0.36
DDB1 Q16531 2/20 0.36
PDK2 Q15119 2/20 0.36
PDK4 Q16654 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CALCRL Q16602 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13314948 0.84 PLD1 (0.49) PLD1CCR5PDE7ACRBNDDB1
SCHEMBL1572587 0.81 PLD1 (0.48) PLD1KCNH2CCR5CRBNDDB1
SCHEMBL14156745 0.80 PLD1 (0.52) PLD1CCR5PDE7ACRBNDDB1
SCHEMBL13804215 0.80 PLD1 (0.54) PLD1OPRM1KCNH2CCR5PDE7A
SCHEMBL13342752 0.79 KCNH2 (0.52) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL15523145 0.78 PDE7A (0.49) PLD1CCR5PDE7APDK2PDK4
SCHEMBL14983900 0.78 KCNH2 (0.46) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL3892412 0.77 CRBN (0.51) PLD1KCNH2CCR5PDE7ACRBN
SCHEMBL8196120 0.77 PLD1 (0.44) PLD1KCNH2CCR5PDE7ACRBN
SCHEMBL8224085 0.77 PLD1 (0.49) PLD1OPRM1KCNH2CCR5PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547694-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-16 US disclosed
US-20070275951-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions MUELLER STEPHAN G 2007-11-29 US disclosed
US-7279471-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275951-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA PLD1 4061/4885OPRM1 42/4885GRIN2D 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.